Evaluating the therapeutic response of intra-vitreal moxifloxacin in acute post-operative (cataract) endophthalmitis.

Objective: To assess the effectiveness and side effects of injecting intra-vitreal moxifloxacin (IV-M) in the treatment of acute post‑operative (cataract) endophthalmitis having visual acuity ≥ hand movements. Study Design: Prospective, Interventional Case Series study. Setting: Eye Department of Qazi Hussain Ahmad Medical Complex, Nowshera. Period: 2018 to Jan. 2021. Material & Methods: Thirty (30) patients with post‑op endophthalmitis who presented within 4 weeks with visual acuity (VA) ≥ hand movements (HM) received two IV-M injection. at 24 hr. interval at an Eye department. Patients with prior history of ocular diseases or intra-vitreals were excluded. Patients were followed up to 12 weeks either for improvement or deterioration of endophthalmitis. No. of patients who attained VA ≥ 6/12 and 6/60 at the 12th week visit were compared with the no. of patients at presentation, by performing statistical analysis. In addition, pre-therapy VA converted into logarithm of minimum angle of resolution (Log MAR) at the time of presentation was compared with post-therapy VA at end of 12th week by using repeated measure ANOVA test. Results: Twenty five (83.3%) patients completely resolved while two patients underwent core vitrectomy. 14 (46.66%) and 22 (73.34%) patients achieved VA ≥ 6/12 and 6/60, respectively at 12th week visit as compared to 04 (13.33%) and 08 (26.66%) patients respectively at the time of presentation (p = 0.043). In the same way, mean Log MAR VA pre-intervention was 0.811 which improved to 0.344 at the 12th week (P < 0.05). We didn’t observe any toxicity to IV-M. Conclusion: Intra-vitreal moxifloxacin was efficacious and safe in the treatment of post-operative (cataract) endophthalmitis.